AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 NOV 13 - (NewsRx.com & NewsRx.net) -- by Maria G. Essig, MS, ELS, senior medical writer - A cost-benefit analysis conducted by a team at Duke University concluded vaccination against influenza and antiviral treatments for influenza-like illness are generally beneficial.
"Physicians have several treatment options for influenza, including vaccination and various antiviral therapies," commented Patrick Y. Lee and his colleagues. "However, the optimal influenza prevention and treatment strategy is unknown."
The investigators analyzed previously published data from one complete influenza season to estimate the value of current influenza therapies in a population of healthy, working adults, aged 18 to 50 years.
Eight treatment modalities were considered: no treatment, vaccination followed by rimantadine, oseltamivir, zanamivir, or no treatment, or rimantadine, oseltamivir, or zanamivir treatment (Economic analysis of influenza vaccination and antiviral treatment for healthy working adults. Annals of Internal Medicine, 2002;137(4):225-231).
Analysis revealed vaccination was more beneficial than nonvaccination in all circumstances. The most cost-effective strategy was vaccination followed by rimantadine treatment, which resulted in a savings of $30.97 compared with no treatment.
In most situations, antiviral therapy was more cost-effective than no treatment. Factors that exerted a large ...
Source: HighBeam Research, Vaccination against and treatment for influenza appear to be...